Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
6.96
+0.08 (1.16%)
At close: Sep 11, 2025, 4:00 PM EDT
6.55
-0.41 (-5.89%)
After-hours: Sep 11, 2025, 4:37 PM EDT

Company Description

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States.

The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.

It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as metastatic melanoma and colorectal cancer.

The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015.

Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.

Actuate Therapeutics, Inc.
Actuate Therapeutics logo
CountryUnited States
Founded2015
IPO DateAug 13, 2024
IndustryBiotechnology
SectorHealthcare
Employees10
CEODaniel Schmitt

Contact Details

Address:
1751 River Run, Suite 400
Fort Worth, Texas 76107
United States
Phone817 887 8455
Websiteactuatetherapeutics.com

Stock Details

Ticker SymbolACTU
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$8.00
CIK Code0001652935
CUSIP Number005083100
ISIN NumberUS0050831009
Employer ID47-3044785
SIC Code2834

Key Executives

NamePosition
Daniel M. SchmittChief Executive Officer, President and Director
Dr. Andrew P. Mazar Ph.D.Co-Founder and Chief Operating Officer
Paul J. Lytle CPAChief Financial Officer
Dr. Alan Kozikowski Ph.D.Scientific Founder and Advisor

Latest SEC Filings

DateTypeTitle
Sep 10, 20258-KCurrent Report
Sep 10, 2025424B5Filing
Sep 9, 2025424B5Filing
Sep 8, 2025EFFECTNotice of Effectiveness
Sep 2, 2025S-3Registration statement under Securities Act of 1933
Aug 18, 2025DRS[Cover] Draft Registration Statement
Aug 14, 202510-QQuarterly Report
Aug 4, 2025EFFECTNotice of Effectiveness
Aug 4, 2025424B3Prospectus
Jul 31, 2025UPLOADFiling